BACKGROUND: The number of elderly people is growing worldwide, and a substantial proportion of them report difficulty with mobility and in performing activities of daily living. The demographic trends have created enormous interest in development of function-promoting anabolic therapies. At present, androgens and myostatin inhibitors are the two leading classes of function-promoting anabolic therapies that are the most advanced in the drug development process. However, clinical development has been slowed by vexing trial design issues. CONCLUSIONS: Clinical investigators, regulatory agencies and the National Institutes of Health must continue working toward a consensus about the indications for study, efficacy outcomes and what differences in functional outcomes are needed to determine sample size estimates.
BACKGROUND: The number of elderly people is growing worldwide, and a substantial proportion of them report difficulty with mobility and in performing activities of daily living. The demographic trends have created enormous interest in development of function-promoting anabolic therapies. At present, androgens and myostatin inhibitors are the two leading classes of function-promoting anabolic therapies that are the most advanced in the drug development process. However, clinical development has been slowed by vexing trial design issues. CONCLUSIONS: Clinical investigators, regulatory agencies and the National Institutes of Health must continue working toward a consensus about the indications for study, efficacy outcomes and what differences in functional outcomes are needed to determine sample size estimates.
Authors: L Katznelson; D I Rosenthal; M S Rosol; E J Anderson; D L Hayden; D A Schoenfeld; A Klibanski Journal: AJR Am J Roentgenol Date: 1998-02 Impact factor: 3.959
Authors: Indrani Sinha-Hikim; Stephen M Roth; Martin I Lee; Shalender Bhasin Journal: Am J Physiol Endocrinol Metab Date: 2003-04-01 Impact factor: 4.310
Authors: Rajan Singh; Jorge N Artaza; Wayne E Taylor; Melissa Braga; Xin Yuan; Nestor F Gonzalez-Cadavid; Shalender Bhasin Journal: Endocrinology Date: 2005-10-06 Impact factor: 4.736
Authors: Shalender Bhasin; Wayne E Taylor; Rajan Singh; Jorge Artaza; Indrani Sinha-Hikim; Ravi Jasuja; Helen Choi; Nestor F Gonzalez-Cadavid Journal: J Gerontol A Biol Sci Med Sci Date: 2003-12 Impact factor: 6.053
Authors: Rajan Singh; Jorge N Artaza; Wayne E Taylor; Nestor F Gonzalez-Cadavid; Shalender Bhasin Journal: Endocrinology Date: 2003-07-24 Impact factor: 4.736
Authors: Amanda M Haidet; Liza Rizo; Chalonda Handy; Priya Umapathi; Amy Eagle; Chris Shilling; Daniel Boue; Paul T Martin; Zarife Sahenk; Jerry R Mendell; Brian K Kaspar Journal: Proc Natl Acad Sci U S A Date: 2008-03-11 Impact factor: 11.205
Authors: Indrani Sinha-Hikim; Jorge Artaza; Linda Woodhouse; Nestor Gonzalez-Cadavid; Atam B Singh; Martin I Lee; Thomas W Storer; Richard Casaburi; Ruoquing Shen; Shalender Bhasin Journal: Am J Physiol Endocrinol Metab Date: 2002-07 Impact factor: 4.310